Drugs / BR1400-2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06889064 | Sep → Oct 2024 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07373613 | Mar 2026 → Feb 2027 expected | essential hypertension | Boryung Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR1400-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07373613 ↗ |